<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inherent or therapy-induced drug resistance is a major clinical setback in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
<SENT sid="1" pm="."><plain>The extensive usage of cytotoxic nucleobases and <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogues in chemotherapy also results in the development of specific mechanisms of drug resistance, such as <z:chebi fb="0" ids="33838">nucleoside</z:chebi> transport or activation deficiencies </plain></SENT>
<SENT sid="2" pm="."><plain>These drugs are <z:chebi fb="0" ids="50266">prodrugs</z:chebi>; and being converted into the active mono-, di-, and <z:chebi fb="0" ids="15266,18036">triphosphates</z:chebi> inside <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells following administration, they affect nucleic acid synthesis, nucleotide metabolism, or sensitivity to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Previously, we actively promoted the idea that the nanodelivery of active nucleotide species, e.g., 5'-<z:chebi fb="0" ids="15266,18036">triphosphates</z:chebi> of <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogues, can enhance drug efficacy and reduce nonspecific toxicity </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we report the development of a novel type of drug nanoformulations, polymeric conjugates of <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogues, which are capable of the efficient transport and sustained release of phosphorylated drugs </plain></SENT>
<SENT sid="5" pm="."><plain>These drug conjugates have been synthesized, starting from cholesterol-modified mucoadhesive polyvinyl alcohol or biodegradable dextrin, by covalent attachment of <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogues through a tetraphosphate linker </plain></SENT>
<SENT sid="6" pm="."><plain>Association of cholesterol moieties in aqueous media resulted in intramolecular polymer folding and the formation of small nanogel particles containing 0.5 mmol/g of a 5'-phosphorylated <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogue, e.g., 5-fluoro-2'-deoxyuridine (floxuridine, FdU), an active metabolite of anticancer drug 5-fluorouracyl (5-FU) </plain></SENT>
<SENT sid="7" pm="."><plain>The polymeric conjugates demonstrated rapid enzymatic release of floxuridine 5'-phosphate and much slower drug release under hydrolytic conditions (pH 1.0-7.4) </plain></SENT>
<SENT sid="8" pm="."><plain>Among the panel of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines, <z:hpo ids='HP_0000001'>all</z:hpo> studied polymeric FdU-conjugates demonstrated an up to 50× increased cytotoxicity in human <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> PC-3, <z:hpo ids='HP_0003002'>breast cancer</z:hpo> MCF-7, and <z:chebi fb="14" ids="32506">MDA</z:chebi>-MB-231 cells, and more than 100× higher efficacy against <z:chebi fb="0" ids="28680">cytarabine</z:chebi>-resistant human T-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (CEM/araC/8) and <z:chebi fb="0" ids="175901">gemcitabine</z:chebi>-resistant follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (RL7/G) cells as compared to free drugs </plain></SENT>
<SENT sid="9" pm="."><plain>In the initial in vivo screening, both PC-3 and RL7/G subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> showed enhanced sensitivity to sustained drug release from polymeric FdU-conjugate after peritumoral injections and significant <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibition </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> these data demonstrate a remarkable clinical potential of novel polymeric conjugates of phosphorylated <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogues, especially as new therapeutic agents against drug-resistant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>